FORT WORTH, Texas, Oct. 26 /PRNewswire-FirstCall/ -- Wound Management Technologies, Inc., through its subsidiary, Wound Care Innovations, announced today that it has reached an agreement with Biocure S.r.l. of Milan, Italy for the distribution of WNDM’s patented molecular form of activated collagen, CellerateRx(R).
“Providing CellerateRx to the European Union through Biocure as part of our penetration of the multi-billion dollar international wound care market is an important part of WNDM’s strategy. We continue to build alliances with reputable distribution networks for our advanced biotechnology and biopharmaceutical products,” said Cathy Bradshaw, President of Wound Care Innovations.
WMI and Biocure S.r.l. would like to take this opportunity to thank Leonardo Zangani, President of Zangani Investor Community, for all of his assistance in the course of the transaction.
About Wound Management Technologies, Inc.
About Biocure S.r.l.
“Safe Harbor” Statement:
CONTACT: Product information, Cathy Bradshaw, +1-954-315-9242; Shareholder
relations, Lucy Singleton, +1-817-820-7080
Web site: http://www.woundmanagementtechnologies.com/
